BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Published: October 6, 2026 | Stock Picks
The thesis
Abbott Laboratories (ABT) has lost roughly 26% over the past year while the S&P 500 gained 14% — yet the business just posted 13% revenue growth, beat earnings for a fourth straight quarter, and analysts still model double-digit earnings growth for next year. The stock now trades at about 18 times forward earnings, sits on its 200-day moving average with momentum near oversold, and carries a fresh buy upgrade into Q3 earnings on October 21. This is the rare setup where valuation, timing, and catalysts all point the same way.
Business snapshot: healthcare’s diversified compounding machine
Abbott is a diversified healthcare company operating in more than 160 countries, with four businesses — Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. Its moat is breadth: recurring-revenue products from diagnostic systems and cardiovascular devices to the FreeStyle Libre glucose-monitoring franchise and infant nutrition create a portfolio that compounds across economic cycles.
The engine is Medical Devices, which grew 8.4% on a comparable basis in Q2 to roughly $6 billion in quarterly sales. Add a 50-plus-year streak of dividend increases and you have one of healthcare’s most shareholder-friendly blue chips.
Financials: what the numbers say
The second quarter of 2026 (reported July 16) showed an operation running hotter than the stock suggests:
- Revenue: $12.59 billion, up 13.0% year over year, ahead of the $12.52 billion consensus.
- Adjusted EPS: $1.31, beating the $1.28 consensus — the fourth consecutive quarter of meeting or beating expectations.
- Company guidance intact: Q3 adjusted EPS of $1.38–$1.46 and full-year 2026 of $5.45–$5.60.
- Consensus trajectory: FY2026 adjusted EPS of $5.52 (+7.2% vs. 2025), rising to $6.08 in FY2027 (+10.1%).
- Balance sheet: debt-to-equity 0.57, net margin 11.65%, ROE 17.69% — conservative leverage for a healthcare giant.
(Related reading: Johnson & Johnson (JNJ) Stock Analysis: A Buy at $256 After a 9% Pullback and Eli Lilly (LLY) Stock: JPMorgan Sees $1,500 — Buy the Pullback at $1,157)
Chart & technicals: sitting on the 200-day line
Abbott closed near $99.27, down 8.36% over the past month and roughly 26% from its 52-week high of $135.37 — while sitting about 21% above the 52-week low of $81.97. The chart structure, with real numbers:
- 200-day moving average: ~$98.60 — the stock is trading about 0.7% above it, a first clean test of long-term support in months.
- 50-day moving average: ~$106.99 — roughly 8% overhead, the first layer of resistance a recovery must reclaim.
- Support: $97–$98 (the 200-day zone); a sustained break opens the path toward the 52-week low near $82.
- RSI (14-day): ~35 — near oversold, the weakest momentum reading of the pullback.
- Volume: ~9.6 million shares on a 20-day average — steady, not panicked selling, which is how bottoms tend to form.
Valuation: 18x forward earnings for a medtech compounder
At $99.27, Abbott trades at roughly 18 times the FY2026 consensus adjusted EPS of $5.52 — inexpensive for a business expected to grow earnings 10% next year. The headline trailing P/E of ~31 is backward-looking and weighed down by acquisition-related amortization and interest from the Exact Sciences deal, which is why the market prices the stock on adjusted numbers.
The PEG ratio of 1.81 sits well below the typical medtech premium. The dividend — $0.63 per quarter, $2.52 annualized, a ~2.55% yield — pays you while the rerating develops. Analyst consensus is Moderate Buy with an average target of $119.80, about 21% above the current price. The revision tape leans constructive: Rothschild & Co Redburn upgraded to Buy with a $127 target on October 2, TD Cowen holds $135, BTIG $134, and RBC $130 — with BofA’s $102 the lone bearish outlier.
Catalysts & what to watch
- Q3 2026 earnings: October 21, before the market opens. Consensus expects adjusted EPS of $1.42–$1.43 vs. $1.30 a year ago (+9–10%). The test: confirming the full-year $5.45–$5.60 guidance.
- Ex-dividend: October 15 ($0.63, payable November 16) — income buyers step in ahead of the date.
- SimpleScreen CRC launched October 1: an FDA-approved blood-based colorectal cancer screening test for adults 45+, with Medicare coverage for eligible Part B patients — a new diagnostics growth lever alongside Cologuard Plus.
- CardioMEMS HF System update approved: patients can now view pulmonary artery pressure readings on smartphones — more fuel for the high-growth devices segment.
- Watch: whether FreeStyle Libre growth re-accelerates and whether China and Nutrition headwinds stabilize.
Risks — honestly stated
- The selloff has real causes. Nutrition and Diagnostics weakness, slower FreeStyle Libre growth, and China pressure are documented, not invented.
- The Exact Sciences acquisition added debt, interest expense, and amortization — balance-sheet and GAAP-earnings drag that takes quarters to digest.
- The downtrend is still intact. The stock is below its 50-day moving average; a break of the 200-day near $98.60 could pull it toward the 52-week low of $81.97.
- The dividend payout ratio is 81.55% — generous but thin, so dividend growth depends on earnings actually hitting that $5.45–$5.60 guide.
Bottom line
Abbott is a premium medtech business in a sentiment trough, not a fundamental one: 13% revenue growth, a fourth straight earnings beat, intact guidance, and a pipeline adding real products — all priced as if none of it mattered. At $99, on the 200-day support line with oversold momentum, the ex-dividend on October 15, and earnings on October 21, this is the discounted-quality entry I would put my own money into today.
Sources:
- https://www.barchart.com/story/news/4900817/abbott-laboratories-quarterly-earnings-preview-what-you-need-to-know
- https://www.tipranks.com/stocks/abt/earnings
- https://www.ad-hoc-news.de/boerse/corporate-news/rothschild-and-co-redburn-raises-target-for-abbott-laboratories-stock-to/70216477
- https://www.ad-hoc-news.de/boerse/corporate-news/abbott-launches-simplescreen-crc-for-abbott-laboratories-stock/70209231
- https://www.americanbankingnews.com/2026/10/04/abbott-laboratories-nyseabt-raised-to-buy-at-rothschild-co-redburn.html
- https://transcriptdaily.com/2026/10/05/abbott-laboratories-nyseabt-upgraded-at-rothschild-co-redburn.html
- https://marketbeat.com/stocks/NYSE/ABT/forecast/
- https://stocknear.com/stocks/ABT
- https://tradersunion.com/news/stocks/show/3587899-abbott-laboratories-slides-1-48percent-today/
Auto-posted by the Bull Lounge research desk.
*Not financial advice. Do your own research.*
Discussion: With Q3 earnings landing October 21, would you buy ABT here at the 200-day — or wait for confirmation that the downtrend has turned?
Log in to vote
